Skip to content

Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene

Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03892798
Acronym
IRF2BPL
Enrollment
34
Registered
2019-03-27
Start date
2018-11-27
Completion date
2024-05-17
Last updated
2024-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder, Dystonia, Movement Disorders, NEDAMSS, Seizures

Keywords

IRF2BPL, NEDAMSS, dystonia, movement disorder, seizures

Brief summary

This protocol serves as a data collection tool for individuals with variants (missense, nonsense, frameshifts) in the IRF2BPL gene (MIM 611720), which causes Neurodevelopmental Regression, Seizures, Autism and Developmental Delay (NEDAMSS, MIM 618088) and may be involved in other neurodevelopmental presentations. This information will be analyzed to develop a better understanding of the findings and progression of symptoms in individuals with variants in the IRF2BPL gene.

Detailed description

Neurodevelopmental Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS) is caused by changes in the IRF2BPL gene. Variants in the gene can also lead to other neurodevelopmental presentations. Due to the limited number of cases that have been described to date, clinicians may have a limited understanding of what types of symptoms can develop in affected individuals and at what age. The purpose of the study is to gather clinical information about progression, treatments and outcomes for patients with variants in IRF2BPL. The investigators will collect information about medical history, growth, development, treatments and the results of previous genetic tests. In some cases, the investigators may also collect tissue samples. This is a non-interventional study that will expand the current understanding of the range of health concerns that can be seen in individuals with changes in the IRF2BPL gene by collecting medical information and samples from a larger group of affected individuals.

Interventions

No interventions are planned

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
2 Months to 80 Years
Healthy volunteers
No

Inclusion criteria

* Living or deceased individuals with variants in the IRF2BPL gene

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
QuestionnaireThroughout study completion, with the assessment completed on average once per year.The investigators will collect information regarding age at development of symptoms, age at diagnosis, method for diagnosis, specific mutations detected, additional complications with age at onset and treatment.

Secondary

MeasureTime frameDescription
Genotype-phenotype correlationsThroughout study completion, with the assessment completed on average once per year.The investigators will assess for correlations between the type of variant in the IRF2BPL gene, the location of the variant, and the clinical presentation and symptoms.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026